Some of the leaders in the frenzied late-stage race to develop a PCSK9 drug watched their stock prices stumble on Friday afternoon as word of the FDA's concern about potential neurocognitive side effects in the cholesterol drug class ripped through Twitter.
Regeneron is starting work on a new manufacturing plant in Limerick, Ireland, that it expects to manufacture drugs that are currently in its pipeline. But already the drugmaker is talking about an expansion and building a fill-and-finish plant nearby, at least according to Ireland's minister of finance.
Regeneron's hot-selling eye drug Eylea has done a lot in its short life, including post $1.4 billion in 2013 U.S. sales--and make the company's veteran CEO, Len Schleifer, into a billionaire.
After 25 years at the helm of one of biotech's best-case scenarios, Regeneron CEO Leonard Schleifer has crossed the $1 billion threshold, according to Forbes, thanks largely to the company's blockbuster eye drug. And, with a stable of promising late-stage treatments waiting in the wings, the Tarrytown, NY, executive's most profitable work may still be ahead of him.
Development officials in Ireland are excited about the spin-off benefits of getting a Regeneron plant in Limerick. The drugmaker is excited about having a new manufacturing facility that will produce the Irish tax benefits that are all the vogue in pharma these days.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
New York-based biopharma Regeneron will sequence DNA from 100,000 patients at Geisinger Health Systems, a healthcare network that serves 3 million people in Pennsylvania.
Yesterday, Regeneron CEO Len Schleifer announced that r ather than the $377 million expected by analysts, Regeneron will report about $400 million in U.S. sales for macular degeneration treatment Eylea in the fourth quarter, Bloomberg reports.
Partners Regeneron and Bayer are hoping to piggy-back on their success with the wet age-related macular degeneration blockbuster Eylea, reuniting to develop a new drug that could become part of a combination therapy for the disease.
Tarrytown, NY-based Regeneron, maker of the hot-selling vision treatment Eylea, says it will hire 300 people for a new plant in Limerick, Ireland, its first plant outside the U.S., once it finishes refurbishing an abandoned Dell computer facility there.